

Rodney E Infante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8428713/publications.pdf>

Version: 2024-02-01

23
papers

2,243
citations

623734

14
h-index

839539

18
g-index

25
all docs

25
docs citations

25
times ranked

2454
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol. <i>Cell</i> , 2009, 137, 1213-1224.	28.9	589
2	NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15287-15292.	7.1	402
3	Identification of Surface Residues on Niemann-Pick C2 Essential for Hydrophobic Handoff of Cholesterol to NPC1 in Lysosomes. <i>Cell Metabolism</i> , 2010, 12, 166-173.	16.2	205
4	Purified NPC1 Protein. <i>Journal of Biological Chemistry</i> , 2008, 283, 1064-1075.	3.4	204
5	Purified NPC1 Protein. <i>Journal of Biological Chemistry</i> , 2008, 283, 1052-1063.	3.4	191
6	Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19316-19321.	7.1	160
7	Continuous transport of a small fraction of plasma membrane cholesterol to endoplasmic reticulum regulates total cellular cholesterol. <i>ELife</i> , 2017, 6, .	6.0	123
8	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 969-986.e7.	16.2	117
9	Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. <i>JCI Insight</i> , 2018, 3, .	5.0	57
10	Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care. <i>Journal of Oncology Practice</i> , 2018, 14, e238-e250.	2.5	53
11	Ostreolysin A and anthrolysin O use different mechanisms to control movement of cholesterol from the plasma membrane to the endoplasmic reticulum. <i>Journal of Biological Chemistry</i> , 2019, 294, 17289-17300.	3.4	27
12	Monitoring and Modulating Intracellular Cholesterol Trafficking Using ALOD4, a Cholesterol-Binding Protein. <i>Methods in Molecular Biology</i> , 2019, 1949, 153-163.	0.9	26
13	Janus kinase inhibitors suppress cancer cachexia-associated anorexia and adipose wasting in mice. <i>JCSM Rapid Communications</i> , 2020, 3, 115-128.	1.6	25
14	Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e211-e220.	2.5	19
15	LIFR-dependent adipocyte signaling in obesity limits adipose expansion contributing to fatty liver disease. <i>IScience</i> , 2021, 24, 102227.	4.1	12
16	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	4.4	12
17	Cytokine-Mediated STAT3 Transcription Supports ATGL/CGI-58-Dependent Adipocyte Lipolysis in Cancer Cachexia. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9
18	The influence of tumour fluorodeoxyglucose avidity and cachexia development on patient survival in oesophageal or gastroesophageal junction cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 128-136.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Primary Tumor Fluorine-18 Fluorodeoxyglucose (18F-FDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
20	Associations of Prior Chronic Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Glucocorticoids With Cachexia Incidence and Survival. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
21	NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a potential step in cholesterol egress from lysosomes.*. <i>FASEB Journal</i> , 2009, 23, 521.5.	0.5	1
22	The impact of NSCLC disease evolution and treatment on pre- and post-diagnosis weight loss and cachexia designation.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24098-e24098.	1.6	1
23	REPLY: "Look for a physical health status surrogate in hepatocellular carcinoma: Have we found the holy grail?". <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0